替加环素对耐甲氧西林金黄色葡萄球菌（包括与家畜相关的菌株）的体外活性。
In vitro activity of tigecycline against methicillin-resistant Staphylococcus aureus, including livestock-associated strains.
机构信息
Laboratory for Microbiology and Infection Control, Amphia Hospital, PO Box 90158 4800 RK, Breda, The Netherlands.
出版信息
Eur J Clin Microbiol Infect Dis. 2010 May;29(5):503-7. doi: 10.1007/s10096-010-0886-2. Epub 2010 Feb 26.
Abstract
The in vitro activity of tigecycline was determined using a well-defined collection of methicillin-resistant Staphylococcus aureus (MRSA) isolates (n = 202), including 33 livestock-associated strains. Susceptibility testing was performed using the Etest system. Among the 202 MRSA strains, three (1.5%) had a minimum inhibitory concentration (MIC) value for tigecycline greater than 0.5 mg/l, which are considered to be resistant. When these strains were tested using Iso-Sensitest medium, the MICs were substantially lower and no resistance was found. This discrepancy warrants further investigations into the preferred test conditions for tigecycline. In conclusion, tigecycline showed good activity against MRSA strains in vitro.
摘要
采用经过明确定义的耐甲氧西林金黄色葡萄球菌（MRSA）分离株（n=202）集合，包括 33 株来自牲畜的分离株，来确定替加环素的体外活性。使用 Etest 系统进行药敏试验。在 202 株 MRSA 菌株中，有 3 株（1.5%）替加环素的最小抑菌浓度（MIC）值大于 0.5mg/L，被认为是耐药的。当使用 Iso-Sensitest 培养基对这些菌株进行测试时，MIC 值显著降低，并未发现耐药性。这种差异需要进一步研究替加环素的首选测试条件。总之，替加环素对体外 MRSA 菌株显示出良好的活性。
相似文献
1
In vitro activity of tigecycline against methicillin-resistant Staphylococcus aureus, including livestock-associated strains.
Eur J Clin Microbiol Infect Dis. 2010 May;29(5):503-7. doi: 10.1007/s10096-010-0886-2. Epub 2010 Feb 26.
2
In vitro activity of linezolid, tigecycline, and daptomycin on methicillin-resistant Staphylococcus aureus blood isolates from adult patients, 2006-2008: stratified analysis by vancomycin MIC.
J Microbiol Immunol Infect. 2011 Oct;44(5):346-51. doi: 10.1016/j.jmii.2011.01.037. Epub 2011 Jan 20.
3
[In vitro activity of tigecycline against methicillin-resistant staphylococci].
Mikrobiyol Bul. 2009 Apr;43(2):211-5.
4
Activity of tigecycline against methicillin-resistant Staphylococcus aureus (MRSA) from respiratory tract sources.
Int J Antimicrob Agents. 2010 Apr;35(4):414-5. doi: 10.1016/j.ijantimicag.2009.11.023.
5
Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
Antimicrob Agents Chemother. 2009 Mar;53(3):1165-9. doi: 10.1128/AAC.00647-08. Epub 2008 Dec 29.
6
Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus.
J Antimicrob Chemother. 2009 Mar;63(3):485-8. doi: 10.1093/jac/dkn513. Epub 2008 Dec 24.
7
Worrisome trends in rising minimum inhibitory concentration values of antibiotics against methicillin resistant Staphylococcus aureus - Insights from a tertiary care center, South India.
Braz J Infect Dis. 2015 Nov-Dec;19(6):585-9. doi: 10.1016/j.bjid.2015.08.005. Epub 2015 Sep 8.
8
Comparative time-kill study of doxycycline, tigecycline, cefazolin and vancomycin against several clones of Staphylococcus aureus.
Curr Clin Pharmacol. 2013 Nov;8(4):332-9. doi: 10.2174/15748847113089990063.
9
Sustained antimicrobial activity of tigecycline against methicillin-resistant Staphylococcus aureus (MRSA) from United States Medical Centers from 2004 through 2008.
J Chemother. 2010 Feb;22(1):13-6. doi: 10.1179/joc.2010.22.1.13.
10
Tigecycline induction of phenol-soluble modulins by invasive methicillin-resistant Staphylococcus aureus strains.
Antimicrob Agents Chemother. 2013 Sep;57(9):4562-5. doi: 10.1128/AAC.00470-13. Epub 2013 Jul 1.
引用本文的文献
1
Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review.
Eur J Clin Microbiol Infect Dis. 2022 Jul;41(7):1003-1022. doi: 10.1007/s10096-020-04121-1. Epub 2021 Jan 5.
2
Biomechanical comparison of tigecycline loaded bone cement with vancomycin and daptomycin loaded bone cements.
Acta Orthop Traumatol Turc. 2020 Sep;54(5):535-540. doi: 10.5152/j.aott.2020.19086.
3
Therapy of intracellular Staphylococcus aureus by tigecyclin.
BMC Infect Dis. 2013 Jun 5;13:267. doi: 10.1186/1471-2334-13-267.
4
Effect of manganese in test media on in vitro susceptibility of Enterobacteriaceae and Acinetobacter baumannii to tigecycline.
J Clin Microbiol. 2012 Sep;50(9):3077-9. doi: 10.1128/JCM.01485-12. Epub 2012 Jun 20.
本文引用的文献
1
High concentrations of manganese in Mueller-Hinton agar increase MICs of tigecycline determined by Etest.
J Clin Microbiol. 2009 Mar;47(3):827-9. doi: 10.1128/JCM.02464-08. Epub 2009 Jan 14.
2
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
Antimicrob Agents Chemother. 2008 Apr;52(4):1430-7. doi: 10.1128/AAC.01538-07. Epub 2008 Feb 19.
3
Emergence of methicillin-resistant Staphylococcus aureus of animal origin in humans.
Emerg Infect Dis. 2007 Dec;13(12):1834-9. doi: 10.3201/eid1312.070384.
4
Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
Clin Microbiol Infect. 2008 Feb;14(2):124-9. doi: 10.1111/j.1469-0691.2007.01888.x. Epub 2007 Dec 10.
5
Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers.
Diagn Microbiol Infect Dis. 2008 Apr;60(4):433-6. doi: 10.1016/j.diagmicrobio.2007.10.016. Epub 2007 Dec 18.
6
Evaluation of the in vitro activity of tigecycline against multiresistant Gram-positive cocci containing tetracycline resistance determinants.
Int J Antimicrob Agents. 2008 Mar;31(3):209-15. doi: 10.1016/j.ijantimicag.2007.03.014. Epub 2007 Jul 23.
7
Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
J Antimicrob Chemother. 2007 Oct;60(4):788-94. doi: 10.1093/jac/dkm258. Epub 2007 Jul 10.
8
Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period.
J Clin Microbiol. 2006 Nov;44(11):3883-6. doi: 10.1128/JCM.01388-06. Epub 2006 Sep 6.
9
Tigecycline: first of a new class of antimicrobial agents.
Pharmacotherapy. 2006 Aug;26(8):1099-110. doi: 10.1592/phco.26.8.1099.
10
Methicillin-resistant Staphylococcus aureus in pig farming.
Emerg Infect Dis. 2005 Dec;11(12):1965-6. doi: 10.3201/eid1112.050428.
Zotero 插件